Neostigmine: how much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent?
Lien
Cynthia A
CA
D000109:Acetylcholine / Q000378:metabolism; D000110:Acetylcholinesterase / Q000494:pharmacology; D000762:Anesthesia Recovery Period; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D006801:Humans; D016343:Monitoring, Intraoperative; D009388:Neostigmine / Q000008:administration & dosage* / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D020127:Recovery of Function
D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D009388:Neostigmine; D000110:Acetylcholinesterase; D000109:Acetylcholine